Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: Evidence for gene-environment interaction?

Pharmacogenetics and Genomics

Volumn 17, Issue 8, 2007, Pages 639-645

  Tan, Xiang Lin ^a   Nieters, Alexandra ^a   Hoffmeister, Michael ^a   Beckmann, Lars ^a   Brenner, Hermann ^a   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Colorectal cancer; Gene environment interaction; Nonsteroidal anti inflammatory drugs; Polymorphisms; TP53 gene

Indexed keywords

ARGININE; NONSTEROID ANTIINFLAMMATORY AGENT; PROLINE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; DRUG USE; ENVIRONMENTAL EXPOSURE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447332275     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3280d5121c     Document Type: Article

References (47)

1. Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999; 81:62-68.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252-266.
3. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005; 162:548-558.
4. Hoffmeister M, Chang-Claude J, Brenner H. Do older adults using NSAIDs have a reduced risk of colorectal cancer? Drugs Aging 2006; 23:513-523.
5. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38:1311-1321.
6. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33:435-465.
7. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003; 14:413-418.
8. Jackson LM, Hawkey CJ. NSAIDs and the GI tract-potential hazards and benefits. Apoptosis 1999; 4:397-402.
9. Hong SP, Ha SH, Park IS, Kim WH. Induction of apoptosis in colon cancer cells by nonsteroidal anti-inflammatory drugs. Yonsei Med J 1998; 39: 287-295.
10. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar A J, Zahurak ML, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109:994-998.
11. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96:491-503.
12. Koutsos MI, Shiff SJ, Rigas B. Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk elderly patients? Drugs Aging 1995; 6:421-425.
13. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222:179-188.
14. Kralj M, Kapitanovic S, Kovacevic D, Lukac J, Spaventi S, Pavelic K. Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. J Cancer Res Clin Oncol 2001; 127:173-179.
15. Ashktorab H, Dawkins FW, Mohamed R, Larbi D, Smoot DT. Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci 2005; 50:1025-1032.
16. Roy B, Beamon J, Balint E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994; 14:7805-7815.
17. James F, Albrechtsen N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. The dual role model for P53 in maintaining genomic integrity. Cell Mol Life Sci 1999; 55:12-27.
18. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
19. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005; 120:7-10.
20. Levine AJ, Chang A, Dittmer D, Notterman DA, Silver A, Thorn K, et al. The p53 tumor suppressor gene. J Lab Clin Med 1994; 123:817-823.
21. Cho KR, Vogelstein B. Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem Suppl 1992; 16G:137-141.
22. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-767.
23. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990; 87:7555-7559.
24. Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000; 190:412-416.
25. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996; 93:15335-15340.
26. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-1100.
27. Dumont P, Leu JI, Della PA III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
28. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108:196-199.
29. Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993; 8:1703-1705.
30. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23:1954-1956.
31. Själander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L et al., P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995; 16:1461-1464.
32. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001; 109:25-34.
33. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991; 86:369-370.
34. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006; 119:1863-1868.
35. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H, et al. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006; 15:99-107.
36. Brenner H, Chang-Claude J, Seiler CM, Sturmer T, Hoffmeister M. Does a negative screening colonoscopy ever need to be repeated? Gut 2006; 55:1145-1150.
37. ATC Index with DDDs. 6 ed. Oslo: WHO Collaborating Centre for Drugs Statistics Methodology; 2003.
38. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 1998; 18:2095-2099.
39. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
40. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55:56-65.
41. Sjalander A, Birgander R, Saha N, Beckman L, Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996; 46:41-48.
42. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12:893-901.
43. Narayanan NK, Narayanan BA, Bosland M, Condon MS, Nargi D. Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer 2006; 119:1586-1598.
44. Ho C-C, Yang XW, Lee T-L, Liao P-H, Yang S-H, Tsai C-H, Chou M-Y. Activation of p53 signalling in acetylsalicyclic acid-induced adoptosis in OC2 human oral cancer cells. Eur J Clin Invest 2003; 33:875-882.
45. Webster GA and Perkins ND. Transcriptional Cross Talk between NF-κB and p53. Mol Cell Biol 1999; 19:3485-3495.
46. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, et al. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 2000; 19:726-736.
47. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995; 16:2233-2236.